Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Nouche, Ramiro Trillo (6506199560)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: The MASTER study
    (2019)
    Valdes-Chavarri, Mariano (57216641409)
    ;
    Kedev, Sasko (23970691700)
    ;
    Neskovic, Aleksandar N. (35597744900)
    ;
    de la Tassa, Cesar Morís (57222430348)
    ;
    Zivkovic, Milan (57535325700)
    ;
    Nouche, Ramiro Trillo (6506199560)
    ;
    González, Nicolas Vázquez (56152454100)
    ;
    Bartorelli, Antonio L. (7005844246)
    ;
    Antoniucci, David (7005655782)
    ;
    Tamburino, Corrado (57212260375)
    ;
    Colombo, Antonio (35354455800)
    ;
    Abizaid, Alexandre (36122299200)
    ;
    McFadden, Eugene (55510816600)
    ;
    García-García, Hector M. (9633803100)
    ;
    Milasinovic, Dejan (24823024500)
    ;
    Stankovic, Goran (59150945500)
    Aims: The MASTER study was designed to compare the performance of a new biodegradable polymer sirolimus-eluting stent (BP-SES) with a bare metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI). Methods and results: The study was a prospective, randomised (3:1), controlled, single-blind multicentre trial that enrolled 500 STEMI patients within 24 hours of symptom onset during 2013-2015. Three hundred and seventy-five patients were treated with BP-SES and 125 with BMS. One hundred and four (104) randomised patients underwent angiographic follow-up at six months. The primary clinical endpoint was target vessel failure (TVF), defined as cardiac death, MI not clearly attributable to a non-target vessel, or clinically driven target vessel revascularisation (TVR) at 12 months. The primary angiographic endpoint was in-stent late lumen loss (LLL) at six months in the angiographic cohort. The major secondary endpoint for safety was a composite of all-cause death, recurrent MI, unplanned infarct-related artery revascularisation, stroke, definite stent thrombosis (ST) or major bleeding at one month. At 12 months, TVF had occurred in 6.1% of BP-SES and 14.4% of BMS patients (pnon-inferiority=0.0004), mainly driven by a higher rate of repeat revascularisation in BMS patients. The safety endpoint occurred in 3.5% of BP-SES and 7.2% of BMS patients (p=0.127). In-stent LLL demonstrated the superiority (p=0.0125) of BP-SES (0.09±0.43 mm) over BMS (0.79±0.67 mm). Conclusions: The study showed clinical non-inferiority and angiographic superiority of BP-SES versus a comparator BMS, suggesting that this novel DES may be a potential treatment option in STEMI. © Europa Digital & Publishing 2019. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback